COVID-19 vaccine from Anhui earns conditional approval
By Wang Xiaoyu |
chinadaily.com.cn |
Updated: 2022-03-02 17:20
Share
Share - WeChat
China has given conditional approval for a recombinant protein subunit COVID-19 vaccine developed by domestic company Anhui Zhifei Longcom Biopharmaceutical, the National Medical Products Administration said on Wednesday.
The vaccine uses purified pieces of the virus' protein to trigger an immune response. It is the first vaccine based on this technology to be approved by the top drug regulator.
In total, five COVID-19 vaccines have been approved for public use in China so far.
- China continues to strengthen protection for trade secrets against criminal breaches
- Drawing China's railways from memory
- 7 found accountable for contaminated tap water in Hangzhou
- HKSAR rescue team, preparation team for Kai Tak sports park commissioning honored for outstanding contributions
- China unveils guideline on advancing high-quality development of copyright sector
- China's High Energy Photon Source targets trial run by end-2025
